Adlai Nortye Ltd
Research Adlai Nortye Ltd (ANL) on Bullrun: market cap USD 1.01B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANL
- ExchangeNASDAQ
- CountrySingapore
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.01B
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 1.01B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 5.00M | -USD 35.53M | -USD 33.64M | n/a | -1.11 | USD 8.06M | USD 26.38M | -USD 8.32M |
| FY2024 | USD 0 | -USD 51.87M | -USD 51.99M | n/a | -1.62 | USD 60.90M | USD 27.23M | USD 25.49M |
| FY2023 | USD 0 | -USD 109.23M | -USD 56.85M | n/a | -7.56 | USD 91.49M | USD 31.55M | USD 75.05M |
| FY2022 | USD 0 | -USD 58.79M | -USD 44.49M | n/a | -1.59 | USD 42.76M | USD 6.54M | -USD 241.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.01B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 56.80M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 98.89M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 331.73M | n/a | n/a | n/a |
About Adlai Nortye Ltd
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adlai Nortye Ltd's market cap?
Adlai Nortye Ltd's market capitalization is USD 1.01B.
What does Adlai Nortye Ltd do?
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.